Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 SUMO-protein ligase PIAS2 (PIAS2), also known as protein inhibitor of activated STAT2, is a member of the PIAS protein family and functions as an E3-type small ubiquitin-like modifier (SUMO) ligase. Its primary role is as a transcriptional co-regulator, mediating SUMOylation of a wide range of transcription factors including STATs, p53, NF-κB, SMADs, and others. PIAS2 modulates cellular gene expression through both activation and repression, impacting numerous biological processes such as immune response, cell cycle, and DNA repair. It plays a crucial role in cytokine signaling—particularly in the JAK/STAT pathway—and is implicated in diverse human diseases, especially cancer, immune and inflammatory disorders, and dementia. Multiple isoforms exist due to alternative splicing. PIAS2's broad regulatory functions make it a potential therapeutic target, although direct inhibitors are not currently clinically available[1][2][3].
SUMOylation of transcription factors and coregulatory proteins, modulating their activity (e.g., inhibiting or activating gene expression through STAT or NF-κB pathways)[1][2][3]. Recruitment of histone deacetylases and other chromatin modifiers, leading to gene silencing[2]. Protein–protein interaction and relocalization of transcriptional regulators within the nucleus[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 SUMO-protein ligase PIAS2 (PIAS2).